Iovance Biotherapeutics (0JDK) Income Statement
Iovance Biotherapeutics Income Statement
Last quarter (Q2 2026), Iovance Biotherapeutics's total revenue was $99.31M, an increase of 65.65% from the same quarter last year. In Q2, Iovance Biotherapeutics's net income was $-47.31M. See Iovance Biotherapeutics’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 263.50M | $ 164.07M | $ 1.19M | $ 0.00 | $ 0.00 | |
| $ 90.32M | $ 40.08M | $ -9.57M | $ 0.00 | $ 0.00 | |
| $ 488.53M | $ 435.35M | $ 450.99M | $ 398.88M | $ 342.70M | |
| Depreciation and Amortization | $ 47.32M | $ 43.61M | $ 33.13M | $ 21.14M | $ 13.98M |
| $ -350.89M | $ -331.40M | $ -414.39M | $ -371.77M | $ -328.27M | |
| $ -398.21M | $ -395.28M | $ -460.56M | $ -398.88M | $ -342.70M | |
| $ 5.16M | $ 20.27M | $ 13.04M | $ 2.98M | $ 451.00K | |
| $ -393.05M | $ -375.00M | $ -447.52M | $ -395.89M | $ -342.25M | |
| $ -390.98M | $ -372.18M | $ -444.04M | $ -395.89M | $ -342.25M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.09 | $ -1.28 | $ -1.89 | $ -2.49 | $ -2.23 |
| Diluted EPS | $ -1.09 | $ -1.28 | $ -1.89 | $ -2.49 | $ -2.23 |
| Weighted Average Shares Outstanding | 357.35M | 289.88M | 235.13M | 159.26M | 153.41M |
| Weighted Average Shares Outstanding (Diluted) | 357.35M | 289.88M | 235.13M | 159.26M | 153.41M |
Currency in USD
